

# Diagnostics, monitoring, and shortening of the treatment of acute haematogenous OsteoMyelitis and Septic Arthritis of childhood

**Submission date**

04/01/2007

**Recruitment status**

No longer recruiting

☐ Prospectively registered

☐ Protocol

**Registration date**

26/02/2007

**Overall study status**

Completed

☐ Statistical analysis plan

☒ Results

**Last Edited**

09/03/2011

**Condition category**

Infections and Infestations

☐ Individual participant data

**Plain English summary of protocol**

Not provided at time of registration

## Contact information

**Type(s)**

Scientific

**Contact name**

Prof Heikki Peltola

**Contact details**

Hospital District of Helsinki and Uusimaa  
HUCH Hospital for Children and Adolescents  
PO Box 281  
Helsinki  
Finland  
00029  
heikki.peltola@hus.fi

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

# Study information

## Scientific Title

## Acronym

OM-SA

## Study objectives

Current treatment of acute paediatric osteoarticular infections can be considerably shortened and otherwise simplified.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Protocol approved by the Ethical Committees of the participating centres (Central Hospital of Päijät-Häme on March 7, 1983, Jorvi Hospital on May 30, 1983, and Helsinki University Hospital on July 25, 1983)

## Study design

Prospective, randomized, noninferiority trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Not specified

## Study type(s)

Treatment

## Participant information sheet

## Health condition(s) or problem(s) studied

Acute bacterial osteoarticular infection of children

## Interventions

Computer-generated list divided patients to receive a long (30 days), or a short (20 days for osteomyelitis, 10 days for septic arthritis) medication. Children being born on an odd day received clindamycin, those born on an even day received first generation cephalosporin. Antimicrobial was given intravenously only for two to four days, the treatment being completed orally. No serum assays were performed. Surgery was kept as minimum, its aim being mainly to obtain an adequate sample for bacteriology.

## Intervention Type

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Clindamycin, cephalosporin

**Primary outcome measure**

Success rate at least one year post-hospitalization. Failure was defined as a case in which treatment for an osteoarticular infection was reinstituted within one year.

**Secondary outcome measures**

All potential defects in the affected bone or joint which, according to the treating paediatrician or orthopaedic surgeon, were likely to leave a residual defect with potential malfunction.

**Overall study start date**

01/01/1983

**Completion date**

01/01/2003

**Eligibility****Key inclusion criteria**

Children aged between three months to 14 years with bacteriologically proven acute haematogenous osteomyelitis, septic arthritis, or their combination

**Participant type(s)**

Patient

**Age group**

Child

**Lower age limit**

3 Months

**Upper age limit**

14 Years

**Sex**

Both

**Target number of participants**

At least 63 in each arm

**Key exclusion criteria**

1. Immunocompromized
2. Other underlying diseases
3. Previous osteoarticular infection

**Date of first enrolment**

01/01/1983

**Date of final enrolment**

01/01/2003

## **Locations**

**Countries of recruitment**

Finland

**Study participating centre**

Hospital District of Helsinki and Uusimaa

Helsinki

Finland

00029

## **Sponsor information**

**Organisation**

HUCH Hospital for Children and Adolescents, University of Helsinki (Finland)

**Sponsor details**

PO Box 281

Helsinki

Finland

00029

**Sponsor type**

Hospital/treatment centre

**ROR**

<https://ror.org/02e8hzf44>

## **Funder(s)**

**Funder type**

Hospital/treatment centre

**Funder Name**

HUCH Hospital for Children and Adolescents, University of Helsinki (Finland)

**Funder Name**

Orion Pharma Ltd (Finland) - decision on funding pending

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/12/2010		Yes	No